Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 100,000 Shares of Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of the business’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $11.67, for a total value of $1,167,000.00. Following the sale, the insider now owns 1,098,499 shares in the company, valued at approximately $12,819,483.33. The trade was a 8.34 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Sarina Tanimoto also recently made the following trade(s):

• On Tuesday, December 10th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $13.16, for a total value of $1,316,000.00.
• On Tuesday, October 15th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $14.88, for a total value of $1,488,000.00.

ARS Pharmaceuticals Trading Up 3.3 %

Shares of NASDAQ SPRY opened at $11.32 on Friday. The company has a 50-day moving average of $14.44 and a 200 day moving average of $12.42. ARS Pharmaceuticals, Inc. has a 12-month low of $5.02 and a 12-month high of $18.51. The stock has a market cap of $1.10 billion, a PE ratio of -22.20 and a beta of 0.88.

Analyst Upgrades and Downgrades

SPRY has been the subject of several research reports. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price objective on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Leerink Partners lifted their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, September 20th. Finally, William Blair upgraded shares of ARS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $24.00.

Hedge Funds Weigh In On ARS Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. J.W. Cole Advisors Inc. raised its holdings in shares of ARS Pharmaceuticals by 10.8% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after acquiring an additional 1,500 shares during the period. nVerses Capital LLC purchased a new stake in shares of ARS Pharmaceuticals in the third quarter valued at about $30,000. Creative Planning increased its position in ARS Pharmaceuticals by 7.0% during the third quarter. Creative Planning now owns 35,263 shares of the company’s stock worth $511,000 after purchasing an additional 2,307 shares during the last quarter. HighTower Advisors LLC raised its stake in ARS Pharmaceuticals by 18.2% during the third quarter. HighTower Advisors LLC now owns 28,310 shares of the company’s stock worth $411,000 after purchasing an additional 4,369 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in ARS Pharmaceuticals by 151.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after purchasing an additional 4,472 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.